drugset / Trial / NCT05867563
Clinical Trial Evaluating the Safety of the TQB2103 for Injection
Phase 1
Unknown
71 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
TQB2103 injection is an antibody-drug conjugate (ADC) targeting claudin (CLDN) 18.2. This study aimed to evaluate the safety and tolerability, pharmacokinetic characteristics and immunogenicity of TQB2103 injection in patients with advanced malignant tumors as well as its initial effectiveness.
Timeline
- Start
- 2023-07-04
- Primary completion
- 2025-05
- Completion
- 2025-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2103 | Other / unclassified | 0.5 mg/kg | Intravenous |
| Subject | TQB2103 | Other / unclassified | 1 mg/kg | Intravenous |
| Subject | TQB2103 | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | TQB2103 | Other / unclassified | 3 mg/kg | Intravenous |
| Subject | TQB2103 | Other / unclassified | 4 mg/kg | Intravenous |
| Subject | TQB2103 | Other / unclassified | 5 mg/kg | Intravenous |